Project - Sublingual insulin+ (fixed dose combination product of insulin and exenatide/liraglutide)

The global human insulin market is projected to surpass USD 40 Billion USD. Our sublingual “insulin+” product will be positioned in a particular segment of this market : it will be prescribed for type II diabetes patients, who do not respond sufficiently to GLP-1 analogues alone.

Such a fixed dose combination is already on the market under the brand name Xultophy, which is a combination of insulin degludec and liraglutide injection.

Advantages of an insulin+ product over pure insulin are as follows :

• More stable blood glucose lowering
• Less risk of unacceptable variations and insulin overshoot